Ozempic weight loss on TikTok: what 25kg claims leave out

What did @_officialkinuthia actually say?

The creator is starting their third semaglutide pen, reporting they have lost "more than 20 kiddies" (kilograms), settling on approximately 25 to 26 kg lost so far. They describe moving from pen to pen on a monthly cadence and express excitement about continued progress, with a stated goal of reaching 90 kg from a starting point implied to be around 148 kg based on the caption's current weight of 123 kg.

There are no specific dose claims, no disease cure language, and no dramatic medical promises. This is largely a personal progress update. The creator is honest about uncertainty in their exact numbers, saying "I'm not really, really sure" about whether it's 25 or 26 kg. That kind of uncertainty is actually more credible than creators who recite suspiciously precise figures.

They also briefly mention a possible hip injury concern, which they quickly set aside. That offhand comment is worth paying attention to, for reasons explained below.

Does the science back this up?

Losing roughly 25 kg over approximately two to three months of semaglutide use would be aggressive but not impossible at higher starting weights. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed average weight loss of 14.9% of body weight over 68 weeks at the full 2.4 mg weekly dose. For someone starting near 148 kg, that would be about 22 kg on average.

Losing 25 kg in a shorter window at a higher starting weight is plausible, especially in early treatment when water weight, glycogen depletion, and rapid appetite suppression combine. However, the pace matters. STEP 1 data showed most weight loss occurring gradually, with maximum effect around weeks 52 to 68. Front-loaded losses are common but often slow substantially after the first few months.

• STEP 1 (Wilding et al., 2021, NEJM): 14.9% mean body weight reduction over 68 weeks
• STEP 5 (Garvey et al., 2022, Nature Medicine): sustained weight loss maintained at two years with continued use
• Withdrawal studies show significant weight regain after stopping (Wilding et al., 2022, Diabetes, Obesity and Metabolism)

What did they get wrong (or right)?

Mostly right, with one notable omission. The weight loss figures are plausible. The monthly pen cadence is consistent with standard semaglutide injection frequency. The creator does not overclaim a cure for anything, does not cite a specific dose, and does not promise results for viewers. That is better than most GLP-1 content on TikTok.

The thing they glossed over is the hip comment. Joint pain during rapid weight loss on GLP-1 therapy is a real and underreported issue. Rapid fat loss can alter gait mechanics and load distribution on joints before musculature adapts. There is also emerging discussion around GLP-1-related muscle mass loss: a secondary analysis by Wilding et al. (2021) noted that roughly 40% of weight lost in STEP 1 was lean mass, not fat. Losing significant lean mass while carrying a high body weight can increase joint stress, not reduce it.

Dismissing a possible hip injury with "anyway, let's start" is not the move. Anyone on semaglutide experiencing joint pain should flag it with their prescriber before continuing, not after their next pen.

What should you actually know?

Semaglutide works. The clinical evidence is strong and consistent across multiple large trials. But "it works" is not the same as "it works the same way for everyone" or "it keeps working indefinitely without management."

A few things viewers should understand before taking this video as a template for their own expectations. First, 25 kg in two to three months is on the faster end of the evidence-supported range. Most people lose weight more gradually. Second, results plateau. The STEP trials show most weight loss occurs in the first year, with diminishing returns after that without dose optimization or lifestyle changes.

Third, and most importantly for this creator specifically: musculoskeletal symptoms during rapid weight loss are not something to casually dismiss. The STEP 1 trial did not specifically track hip pain, but rapid body composition changes at high starting weights carry real orthopedic risk.

• GLP-1 therapy requires ongoing medical supervision, not just pen delivery
• Weight regain after stopping semaglutide averages about two-thirds of lost weight within one year (Wilding et al., 2022)
• Lean mass preservation strategies, including resistance training and adequate protein, are not optional extras